---
link: https://www.statnews.com/2025/03/03/protagonist-therapeutics-rusfertide-polycythemia-vera/
---

An experimental medicine from Protagonist Therapeutics stabilized red blood cells and improved symptoms in patients with a rare blood cancer â€” achieving the efficacy goals of a Phase 3 study. The companies are developing the drug as a new treatment for polycythemia vera, a type of blood cancer that causes the overproduction of red blood cells. Log in Monthly $39 Totals $468 per year Totals $468 per year Starter $30 for 3 months, then $399/year Then $399/year Annual $399 Save 15% Save 15% 11+ Users Custom Savings start at 25%!